Andrew C. Edmondson, MD, PhD, is an attending physician with the Metabolic Disease Program and the Division of Human Genetics at Children’s Hospital of Philadelphia.

As a committed physician-scientist, his research interests focus on rare neurometabolic genetic disorders known as congenital disorders of glycosylation (CDG). His specific passion lies in elucidating the molecular mechanisms of these diseases and translating that knowledge to improve patient clinical care. Although key proteins involved in neurotransmitter release, neuronal cell signaling, and cell migration events are glycosylated, our understanding of the role of glycosylation in these processes is rudimentary. The genetic basis of CDG provides an opportunity to identify the neurobiological functions of glycosylation using mouse models and glycoproteomics. He believes that an in-depth study of CDG pathophysiology will provide fundamental insights into critical aspects of human glycobiology leading to new discoveries with broad applications in human health. My research program focuses on elucidating the critical role of glycosylation in human neurological function, understanding the mechanisms of CDG pathophysiology, and developing novel therapeutics targeting glycosylation pathways.

Education:
BS (Microbiology and Russian, minors in Molecular Biology and Chemistry, University Honors) Brigham Young University, 2004.
MD/PhD University of Pennslyvania, 2013.

Post-Graduate Training
Resident, Pediatrics/Genetics, Children's Hospital of Philadelphia, 2013-2017.
Clinical Fellow, Clinical Biochemical Genetics, Children's Hospital of Philadelphia, 2017-2018.
Post-Doctoral Research Fellow, Children's Hospital of Philadelphia and University of Pennsylvania, 2018-2020.